94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
EDITORIAL article
Front. Pharmacol.
Sec. Neuropharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1599083
This article is part of the Research Topic Neuropharmacological Intervention for Severe Mental Illness and Suicide Prevention View all 11 articles
Editorial: Neuropharmacological Intervention for Severe Mental Illness and Suicide Prevention
Provisionally accepted- 1 Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
- 2 Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Veneto, Italy
- 3 Department of Brain Biochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
Severe mental illnesses (SMI), including major depressive disorder, bipolar disorder, and 16 schizophrenia, are leading contributors to disability worldwide and are associated with an elevated risk 17 of suicide. Despite advancements in pharmacological and non-pharmacological interventions, a 18 substantial proportion of individuals with SMI continue to experience persistent symptoms, treatment 19 resistance, and significant comorbidities. These challenges underscore the critical need for novel and 20 more effective therapeutic strategies. Understanding how different medications affect both core 21 psychiatric symptoms and suicide risk remains a key area of research. 22The collected publications present data derived from human subjects with mental illnesses, including 23 post-mortem analyses, as well as from preclinical animal models.
Keywords: Arteminisin, atorvastatin, Dezocine, ferroptosis, Neuroinflammation, neurotrophic factors, treatment-resistant depression
Received: 24 Mar 2025; Accepted: 27 Mar 2025.
Copyright: © 2025 Litwa, Comai and Zelek-Molik. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ewa Litwa, Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
Stefano Comai, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, 35122, Veneto, Italy
Agnieszka Zelek-Molik, Department of Brain Biochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.